Inhibitory effects of fucoxanthinol on the viability of human breast cancer cell lines MCF-7 and MDA-MB-231 are correlated with modulation of the NF-kappaB pathway

Cell Biology and Toxicology

Volumn 30, Issue 3, 2014, Pages 157-167

  Rwigemera, Arlette ^a   Mamelona, Jean ^a   Martin, Luc J ^a  

^a UNIVERSITÉ DE MONCTON   (Canada)

Author keywords

Apoptosis; Fucoxanthin; Fucoxanthinol; MCF 7; MDA MB 231; p65; PARP; Viability

Indexed keywords

DRUG METABOLITE; FUCOXANTHIN; FUCOXANTHINOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; PROTEIN P52; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELB; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; BETA CAROTENE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RELA PROTEIN, HUMAN; RELB PROTEIN, HUMAN; SOX9 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA; XANTHOPHYLL;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER PREVENTION; CELL VIABILITY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; FEMALE; MCF 7 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BETA CAROTENE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; MCF-7 CELLS; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; XANTHOPHYLLS;

EID: 84903541432     PISSN: 07422091     EISSN: 15736822     Source Type: Journal    
DOI: 10.1007/s10565-014-9277-2     Document Type: Article

References (63)

1. Aggarwal BB. Apoptosis and nuclear factor-kappa B: a tale of association and dissociation. Biochem Pharmacol. 2000;60:1033-9.
2. Asai A, Sugawara T, Ono H, Nagao A. Biotransformation of fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos Biol Fate Chem. 2004;32:205-11. (Pubitemid 38176937)
3. Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011;13:11-22.
4. Beppu F, Niwano Y, Sato E, Kohno M, Tsukui T, Hosokawa M, et al. In vitro and in vivo evaluation of mutagenicity of fucoxanthin (FX) and its metabolite fucoxanthinol (FXOH). J Toxicol Sci. 2009a;34:693-8.
5. Beppu F, Niwano Y, Tsukui T, Hosokawa M, Miyashita K. Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice. J Toxicol Sci. 2009b;34:501-10.
6. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
7. Chakravarty G, Rider B, Mondal D. Cytoplasmic compartmentalization of SOX9 abrogates the growth arrest response of breast cancer cells that can be rescued by trichostatin A treatment. Cancer Biol Ther. 2011;11:71-83.
8. Das SK, Hashimoto T, Shimizu K, Yoshida T, Sakai T, Sowa Y, et al. Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim Biophys Acta. 2005;1726:328-35.
9. Desrivières S, Kunz C, Barash I, Vafaizadeh V, Borghouts C, Groner B. The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mammary Gland Biol Neoplasia. 2006;11:75-87. (Pubitemid 44309191)
10. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516. (Pubitemid 46911891)
11. Fan Y, Dutta J, Gupta N, Fan G, Gélinas C. Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol. 2008;615:223-50.
12. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin C-Y, et al. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res. 2009;69:8918-25.
13. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ Mol Biol J Am Assoc Cancer Res. 1997;8:1267-76. (Pubitemid 28008723)
14. Garcia R, Bowman TL, Niu G, Yu H,Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20:2499-513. (Pubitemid 32531347)
15. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195-224.
16. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344-62.
17. Hsieh F-C, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun. 2005;335:292-9. (Pubitemid 41140220)
18. Jänicke RU. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat. 2009;117:219-21.
19. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
20. Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab. 2005;16:46-52. (Pubitemid 40270849)
21. Kang DW, Lee JY, Oh DH, Park SY, Woo TM, Kim MK, et al. Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells. Exp Mol Med. 2009;41:678-85.
22. Kannaiyan R,Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis Int J Program Cell Death. 2011;16:1028-41.
23. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-63. (Pubitemid 30365393)
24. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221-7.
25. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53:3976-85. (Pubitemid 23267698)
26. Kim K-N, Heo S-J, Kang S-M, Ahn G, Jeon Y-J. Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol Vitro. 2010a;24:1648-54.
27. Kim K-N, Heo S-J, Yoon W-J, Kang S-M, Ahn G, Yi T-H, et al. Fucoxanthin inhibits the inflammatory response by suppressing the act ivation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol. 2010b;649:369-75.
28. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285:1-24. (Pubitemid 34246317)
29. Konishi I, Hosokawa M, Sashima T, Kobayashi H, Miyashita K. Halocynthiaxanthin and fucoxanthinol isolated from Halocynthia roretzi induce apoptosis in human leukemia, breast and colon cancer cells. Comp Biochem Physiol Toxicol Pharmacol. 2006;142:53-9. (Pubitemid 43142054)
30. Kotake-Nara E, Asai A, Nagao A. Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells. Cancer Lett. 2005;220:75-84. (Pubitemid 40312020)
31. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factorkappaB: its role in health and disease. J Mol Med Berl Ger. 2004;82:434-48. (Pubitemid 39044283)
32. Lahusen T, Fereshteh M, Oh A,Wellstein A, Riegel AT. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res. 2007;67:7256-65. (Pubitemid 47206554)
33. Le Marchand L, Hankin JH, Kolonel LN, Beecher GR, Wilkens LR, Zhao LP. Intake of specific carotenoids and lung cancer risk. Cancer Epidemiol Biomark Prev. 1993;2:183-7.
34. Lee J-Y, Lee M-S, Choi H-J, Choi J-W, Shin T, Woo H-C, et al. Hexane fraction from Laminaria japonica exerts antiinflammatory effects on lipopolysaccharide-stimulated RAW 264.7 macrophages via inhibiting NF-kappaB pathway. Eur J Nutr. 2013;52:409-21.
35. Liu J, Jiang Z, Xiao J, Zhang Y, Lin S, Duan W, et al. Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine Int J Phytother Phytopharm. 2009;16:1006-13.
36. Lordan S, Ross RP, Stanton C. Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic diseases. Mar Drugs. 2011;9:1056-100.
37. Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun. 2005;332:392-7. (Pubitemid 40724991)
38. Malki S, Nef S, Notarnicola C, Thevenet L, Gasca S, Méjean C, et al. Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation. EMBO J. 2005;24:1798-809. (Pubitemid 40769499)
39. Matsuno T. Aquatic animal carotenoids. Fish Sci. 2001;67:771-83. (Pubitemid 33593592)
40. Müller P, Crofts JD, Newman BS, Bridgewater LC, Lin C-Y, Gustafsson J-A, et al. SOX9 mediates the retinoic acid-induced HES-1 gene expression in human breast cancer cells. Breast Cancer Res Treat. 2010;120:317-26.
41. Nakshatri H, Goulet Jr RJ. NF-kappaB and breast cancer. Curr Probl Cancer. 2002;26:282-309.
42. Nakshatri H, Bhat-Nakshatri P,Martin DA, Goulet Jr RJ, Sledge Jr GW. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997;17:3629-39. (Pubitemid 27281838)
43. Nishikawa S, Hosokawa M, Miyashita K. Fucoxanthin promotes translocation and induction of glucose transporter 4 in skeletal muscles of diabetic/obese KK-A(y) mice. Phytomedicine. 2012;19:389-94.
44. Nishino H, Murakoshi M, Tokuda H, Satomi Y. Cancer prevention by carotenoids. Arch Biochem Biophys. 2009;483:165-8.
45. Peng J, Yuan J-P, Wu C-F, Wang J-H. Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs. 2011;9:1806-28.
46. Saegusa M, Hashimura M, Suzuki E, Yoshida T, Kuwata T. Transcriptional up-regulation of Sox9 by NF-κB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14(ARF)/p53/p21(WAF1) pathway. Am J Pathol. 2012;181:684-92.
47. Schreiber E, Matthias P, Müller MM, Schaffner W. Rapid detection of octamer binding proteins with «mini-extracts», prepared from a small number of cells. Nucleic Acids Res. 1989;17:6419. (Pubitemid 19198635)
48. Shiratori K, Ohgami K, Ilieva I, Jin X-H, Koyama Y,Miyashita K, et al. Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res. 2005;81:422-8. (Pubitemid 41356505)
49. Slattery ML, Benson J, Curtin K, Ma KN, Schaeffer D, Potter JD. Carotenoids and colon cancer. AmJ Clin Nutr. 2000;71:575-82. (Pubitemid 30061239)
50. Soldani C, Lazzè MC, Bottone MG, Tognon G, Biggiogera M, Pellicciari CE, et al. Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where? Exp Cell Res. 2001;269:193-201. (Pubitemid 32907160)
51. Sugawara T, Baskaran V, Tsuzuki W, Nagao A. Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J Nutr. 2002;132:946-51. (Pubitemid 34493558)
52. Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, et al. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells. 2013;31:1454-66.
53. Tanaka T, Shnimizu M, Moriwaki H. Cancer chemoprevention by carotenoids. Mol. 2012;17:3202-42.
54. Wang J, Chen S, Xu S, Yu X, Ma D, Hu X, et al. In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice. Mar Drugs. 2012;10:2055-68.
55. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res. 2005;123:158-69. (Pubitemid 40094658)
56. Yamamoto K, Ishikawa C, Katano H, Yasumoto T, Mori N. Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett. 2011;300:225-34.
57. Yu R-X, Hu X-M, Xu S-Q, Jiang Z-J, Yang W. Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via JAK/STAT signal pathway. Eur J Pharmacol. 2011;657:10-9.
58. Yuan T, Wang Y, Zhao ZJ, Gu H. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem. 2010;285:14861-70.
59. Zeiss CJ. The apoptosis-necrosis continuum: insights from genetically altered mice. Vet Pathol. 2003;40:481-95. (Pubitemid 38393553)
60. Zhang S,Hunter DJ, FormanMR, Rosner BA, Speizer FE, Colditz GA, et al. Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst. 1999;91:547-56. (Pubitemid 29157064)
61. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer. 2005a;12 Suppl 1:S37-46. (Pubitemid 41398155)
62. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, et al. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol. 2005b;37:1130-44. (Pubitemid 40311751)
63. Zubair A, Frieri M. Role of nuclear factor-κB in breast and colorectal cancer. Curr Allergy Asthma Rep. 2013;13:44-9.